These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16222306)

  • 1. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.
    Bartlett JB; Tozer A; Stirling D; Zeldis JB
    Br J Cancer; 2005 Sep; 93(6):613-9. PubMed ID: 16222306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide.
    Weisel K; Kanz L
    Recent Results Cancer Res; 2014; 201():347-57. PubMed ID: 24756803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of thalidomide and its analogues: implications for anticancer therapy.
    Teo SK
    AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
    Shortt J; Hsu AK; Johnstone RW
    Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous adverse reactions to lenalidomide.
    Imbesi S; Allegra A; Calapai G; Musolino C; Gangemi S
    Allergol Immunopathol (Madr); 2015; 43(1):88-91. PubMed ID: 24998775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory drugs.
    Crane E; List A
    Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
    Guirguis AA; Ebert BL
    Curr Opin Cell Biol; 2015 Dec; 37():61-7. PubMed ID: 26512454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
    Shah SR; Tran TM
    Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
    Leitch HA; Buckstein R; Shamy A; Storring JM
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory therapy for myelodysplastic syndromes.
    Sokol L; List AF
    Int J Hematol; 2007 Nov; 86(4):301-5. PubMed ID: 18055335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
    Madan S; Lacy MQ; Dispenzieri A; Gertz MA; Buadi F; Hayman SR; Detweiler-Short K; Dingli D; Zeldenrust S; Lust J; Greipp PR; Rajkumar SV; Kumar S
    Blood; 2011 Aug; 118(7):1763-5. PubMed ID: 21673347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
    Vallet S; Witzens-Harig M; Jaeger D; Podar K
    Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide, a thalidomide derivative, shows promise in various applications.
    Oestreicher P
    ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
    [No Abstract]   [Full Text] [Related]  

  • 17. Lenalidomide: the emerging role of a novel targeted agent in malignancies.
    Kalmadi S; Baz R; Mahindra A
    Drugs Today (Barc); 2007 Feb; 43(2):85-95. PubMed ID: 17353946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The thalidomide saga.
    Melchert M; List A
    Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [IMiDs in hematology].
    Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
    Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
    Palumbo A; Freeman J; Weiss L; Fenaux P
    Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.